Recent News Releases
Latest CSL News
CSL Media Statement on COVID19 Vaccine Manufacture
Development of the University of Queensland’s vaccine candidate remains CSL’s priority.
At White House Roundtable, Paul Perreault Urges People to Donate Plasma in the Fight Against COVID-19
Inaccurate Report of COVID-19 Vaccine Agreement
The report made by the Courier Mail and other media agencies today that an agreement has been struck to specifically secure supply, when a vaccine is available, for Queensland, is incorrect.
Rare Diseases in Asia-Pacific
Economist Intelligence Unit (EIU) Report launched today reveals only one in three rare disease patients receives the best-available, evidence-based care.
Less than a third of surveyed healthcare professionals (HCPs) in Australia encounter a rare disease patient more than once every six months.
Across APAC, 94% of rare conditions have no approved medical treatment, highlighting need to shift towards the provision of non-medical services.
CSL’s Global Role in Battling COVID-19
Here is how CSL is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19
UQ COVID 19 Vaccine to Commence Human Trials
Today, the first human trials using the University of Queensland’s (UQ) COVID-19 vaccine have commenced in Australia
CSL Behring Begins Trial for Respiratory Distress
Phase II placebo-controlled study will assess the safety and efficacy of CSL312 for the treatment of patients with severe respiratory distress due to COVID-19 related pneumonia.
CSL Behring now evaluating 5 approaches to preventing and treating COVID-19.
CSL Behring Gene Therapy Agreement with uniQure
Unique gene therapy has the potential to be one of the first to market treatments to provide potentially long-term benefits with only one dose.
CSL Behring builds on legacy of delivering innovative treatment options for people with Hemophilia B.
CSL Behring Presents Results for Garadacimab
Investigational Monoclonal Antibody Granted U.S. FDA Orphan Drug Designation
CSL Behring to Acquire Biotech Company Vitaeris
Builds on CSL Behring’s promise and commitment to the transplant community.
Deal accelerates the addition of clazakizumab, an anti-IL6 MAB currently in phase III development for treatment of chronic active antibody-mediated rejection, into CSL Behring’s portfolio.
UQ, CEPI and CSL partner for COVID-19 vaccine
• CSL appointed Trusted Manufacturer for University of Queensland’s “molecular clamp” enabled COVID-19 vaccine candidate
• CEPI and CSL will share costs associated with the clinical development and manufacture of the vaccine candidate
• A vaccine is anticipated to be available in 2021 if clinical trials are successful
2021 CSL Centenary Fellowships
Applications are now open for the 2021 CSL Centenary Fellowships, which are offered to outstanding mid-career scientists seeking to undertake world-class medical research at an Australian academic institute.
Development of COVID-19 immunoglobulin commences
Plasma-derived therapeutic with potential to treat serious complications of COVID-19.
CSL Behring and SAB Biotherapeutics Join Forces
King of Prussia, Pa. and Sioux Falls, S.D.
COVID-19 treatment candidate, a high-potency immunotherapy delivering human polyclonal antibodies targeted to SARS-CoV-2, generated from SAB’s novel platform technology, on-track for clinical evaluation as early as summer
Collaborating on Potential COVID-19 Therapy
Osaka, JAPAN, and King of Prussia, PA, USA
Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19
Our Offer To Help Battle Coronavirus
To speed treatments, global biotech leader CSL offers to lend the company’s expertise in science and manufacturing.
CSL Ranks Among Best Employers for Diversity
Forbes Magazine named CSL among its Best Employers for Diversity 2020. The annual rankings, which measure diversity across six different categories, are based on an independent survey of more than 60,000 employees working in a range of industries.
Senior Manager, Communications
Phone: +61 429 609 762